Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lotus Walk is helping to determine market potential and deciding which path forward is best. Not necessarily "find"
“We look forward to working with Innovation Pharmaceuticals to help them determine the market potential and the best path forward to create value.”
Of which notable progress is being made...must be a long phone call.
Exactly. But you stated it better.
I still think LW was engaged to help them decide the correct value for a deal or deals. Not to start over or restart. In other words, not sign a final deal without more professional research. From PR statements they are in advanced negotiations making notable progress. In terms of more shares authorized...maybe a decision to move forward with UC.
You don't believe the company is in advanced negotiations with pharma companies?
Definitely agree. My comment was more from a perspective that it will generate positive press...or should. Clearly, the price walk down is coming from the increased share offering and lack of immediate news.
Seems to me to be minimizing B OM because of lack of breakthrough and lack of partner. Understandable. Or we could just be haggling over true value of B OM. I'm sure the partner wants low risk and best deal. Same as us.
Seems to me the TPIV 200 if positive would certainly increase the share price.
Much higher than I was thinking given the productivity and delivery method. Wondering where the cost would be.
Seems to me Leo wants to partner and grow the company; not get a buyout of 200% from here.
Has it been stated or has anyone guessed how much a B OM phase 3 would be? I wouldn't think too expensive. Maybe phase 3 is delayed partially due to number of patients available but certainly lack of funding is the reason. Seems we would split the trial and run part through Europe using a partner for Europe.
Hoping we get an update on K soon. Per company...
As we continue to advance the clinical development of our Brilacidin programs in Oral Mucositis and Inflammatory Bowel Disease, the Company concurrently plans to devote resources to Kevetrin, including completing remaining bridging toxicology work toward developing Kevetrin in oral form. An orally-delivered Kevetrin would likely enhance the therapeutic benefits based on its pharmacokinetics, and broaden its market potential by meeting cancer patient’s strong preference for oral meds.
I'm not aware of the exact $ amount. However, what is clear to me is the total amount of milestone revenue and royalties. Also clear to me is that the company will not pay any development or commercial cost. Furthermore, the cost to develop UC could be lessened if somehow the UP development provides them with some direction. Then again, the upfront money may not mean much if a B OM deal is struck. Expecting to hear some direction this week.
Splitting hairs and missing the point. Fact is the non-dilutive capital is funding the oral development of B UC.
Sorry, covers oral B UC trial
Then not sure why Dr B said it covers substantially the cost of the B UP oral trial.
Can someone explain TPIV 200 being developed by Dr Knutson at Mayo yet it being owned by the company? In the recent article it does seem to imply Mayo discovered and owns.
Maybe there's an agreement of some sort.
The initial payment from B UP covers the upcoming B UC trial. Hopefully moving forward with K pill.
From Article:
But the fact is, Knutson said immunologists at Mayo already have two cancer vaccines against Triple Negative Breast Cancer and HER2 Positive Breast Cancer, respectively. They’re also working on a third against ductal carcinoma in situ, or DCIS, a noninvasive breast cancer that brings a staggering 300,000 new cases a year to oncologists in the United States.
From Markers site:
A Phase IB Trial of Neoadjvuant Multi-epitope HER2 Peptide Vaccine in Patients with HER2-expressing DCIS
This protocol details an interventional clinical study examining the safety and efficacy of a degenerate subdominant HER2 specific helper T cell epitope vaccine (H2NVAC) in patients with HER2-expressing ductal carcinoma in situ (DCIS). The ultimate goal of this vaccine is to prevent future invasive breast cancer among patients who are diagnosed with DCIS. However, the focus of this study is safety and efficacy. The vaccine consists of 4 peptide epitopes (15-18 amino acids in length) derived from the HER2 protein. These peptides are derived from HER2 and were selected based upon their recognition by lymphocytes from women with prior HER-2 positive breast cancer. To enhance immunity, the peptides are admixed with the adjuvant GM-CSF. Patients will receive four bi-monthly vaccinations followed by surgery as diagrammed below; observation includes periodic blood draws to assess toxicity and immune responses, as well as periodic echocardiography to assess left ventricular ejection fraction.
From Nov 16 2018 article...The U.S. Department of Defense (DoD) has awarded Mayo Clinic researchers $11 million to conduct a Phase 2 trial investigating the TPIV110 vaccine, in combination with Herceptin (trastuzumab), as a therapy for women with HER2-positive breast cancer. The grant was awarded to Keith L. Knutson, PhD, professor of Immunology in the Department of Immunology, and Saranya Chumsri, MD, from the Division of Hematology and Oncology at Mayo Clinic in Jacksonville, Florida.
So, if all goes well meaning partnerships on BOM and K, we will still need to sell 250k shares a day? Does that imply we will then move other B indications forward?
Makes me wonder why the company update will be in coming weeks instead of this week.
If proves true, then best to partner with another company to uplist. Wondering why mgt seems so excited.
A possible option is to combine with another company, I would think. Wonder if could uplift going this route.
I'm not a day trader, but I know what the ask is. I'm just not sure how accumulating more would impact you negatively when price is on the way up. But, thank you.
Thought you were accumulating? What changed your mind?
Of which notable progress (negotiations) is being made...whatever that means.
I'm not sure, but I can say the stock is cheap considering a net market cap of $100m when factoring cash/receivable and no debt.
My comment on B OM related to management's belief in the potential market size. May have to sacrifice some on upfront payment but partner pay future development costs.
I do not believe we will have a deal by 10Q filing in Nov, but do believe an announced term sheet will happen before then.
A third of their pipeline in P was considered by Leo to be more of a risk of failure anyway. In my opinion, B OM deal will be done with low initial payments, but higher royalties due to the unknown market potential. I believe the company will spend its resources developing B IBD and K until successfully pill trials...not B OM.
I live in Ann Arbor but unfortunately not able to go to the meeting. Stuck at work this week finishing a budget. Was there a list started for the questions?
About that time to buy more shares.
Would like to see the CFO buy shares. Was a good sign that Peter bought some. However, I'm a longer term holder, so would like to see it stay down for a while to accumulating more.
Anyone guess what market cap might be if upcoming trials are successful ?
The contract indicates a $1M payment at start of phase 3.
You mean Sept 19? Maybe. Just depends on my schedule. Would like to, of course. 2 hour drive isn't too bad.
I live in Ann Arbor. Grand Rapids is good 2 hours away. If so, must be he lives in Grand Rapids then. Detroit would be much closer if Ann Arbor was his turf.
Wonder which indications they are making notable progress with advanced negotiations.
Large enough for the oral B UC trial. I'm just not sure if the scope and cost.
Ah. Maybe the upcoming clinical trial is a partial trial.
Per corporate update..
The initial payment will help cover substantially the costs of our upcoming clinical study of oral-dosed Brilacidin currently being developed for treating Ulcerative Colitis (UC).